Great Point Partners

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company’s primary aim is to address female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Context's lead program is Apristor (Onapristone XR), an investigational drug currently in Phase 2 trials for treating progesterone receptor positive metastatic breast and ovarian cancers. The company is also advancing CTX-030916, a potential oral antiprogestin designed for uterine fibroids and endometriosis. Additionally, Context is engaged in a discovery-stage program targeting Sigma1 and has developed CTIM-76, a bispecific antibody aimed at redirecting T-cell-mediated lysis towards malignant cells expressing CLDN6. Through its focused pipeline, Context Therapeutics is committed to creating effective treatments for patients with solid tumors.

Zura Bio is a clinical-stage biotechnology company that develops innovative therapies for immune and inflammatory disorders. The company focuses on advancing its programs through phase 2 development, specifically targeting auto-immune illnesses. One of its key assets, ZB-168, is an anti-IL7R inhibitor designed to address disorders linked to the biological pathways of IL7 and TSLP, building on data from phase 1b studies related to type 1 diabetes. Additionally, Zura Bio is progressing the phase 2 clinical development of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33. Through these efforts, Zura Bio aims to create effective therapeutic solutions for patients suffering from various immune-related conditions.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Ludi is a health care technology and physician-advocacy firm that simplifies the way hospitals and health systems track, manage, and audit payments to their physicians. Ludi’s award-winning flagship product DocTime Log is the original physician timekeeping and financial management system designed to help hospitals take control of their physician spend and the operational processes that drive it. They modernize what’s typically a cumbersome, paper-based process for hospitals, and transform it into a modern physician-focused approach. Ludi was founded in 2012 and is based in Nashville, Tennessee, USA.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins. The company’s lead product candidates include ARV-110, a proteolysis-targeting chimera (PROTAC) currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. Additionally, Arvinas is developing other PROTACs aimed at degrading various androgen receptor mutations and has initiatives focused on treating neurodegenerative diseases, including tauopathies. Arvinas collaborates with major pharmaceutical companies such as Pfizer, Genentech, Roche, and Bayer to advance its innovative therapeutic approaches. Founded in 2015, Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening conditions through its unique protein degradation technology.

Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients with immune diseases. Its primary product candidate, TOUR006, is a fully human monoclonal antibody that targets interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The company leverages over twenty years of clinical and commercial experience associated with the anti-IL-6 and anti-IL-6 receptor antibody class, which has effectively treated over a million patients suffering from a range of autoimmune conditions. Tourmaline Bio is committed to addressing the needs of individuals with life-altering immune diseases through its innovative therapeutic approaches.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and disorders of the central nervous system, particularly those related to psychiatric conditions such as depression and anxiety. The company's main product candidates include PH94B, a neuroactive nasal spray poised for Phase III trials aimed at treating acute anxiety in adults with social anxiety disorder, and PH10, another nasal spray in preparation for Phase 2b development for major depressive disorder. Additionally, AV-101, an oral prodrug candidate, is being developed for multiple indications, including major depressive disorder, suicidal ideation, and neuropathic pain. VistaGen has established various licensing and collaboration agreements with other firms to enhance its research and development efforts, including a strategic partnership for the clinical development of PH94B in select Asian markets. Founded in 1998, VistaGen is headquartered in South San Francisco, California.

Zura Bio is a clinical-stage biotechnology company that develops innovative therapies for immune and inflammatory disorders. The company focuses on advancing its programs through phase 2 development, specifically targeting auto-immune illnesses. One of its key assets, ZB-168, is an anti-IL7R inhibitor designed to address disorders linked to the biological pathways of IL7 and TSLP, building on data from phase 1b studies related to type 1 diabetes. Additionally, Zura Bio is progressing the phase 2 clinical development of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33. Through these efforts, Zura Bio aims to create effective therapeutic solutions for patients suffering from various immune-related conditions.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.

iXCells Biotechnologies specializes in preclinical drug discovery solutions, offering services that focus on disease-relevant cellular models. The company provides cell biology and technology services aimed at assisting the academic, biotech, and pharmaceutical sectors in the development of therapeutic drugs and disease models. By enabling clients with innovative technologies and comprehensive support, iXCells Biotechnologies accelerates the pace of drug discovery, contributing to advancements in the field of medical research.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Established in 2005 with headquarters in Jersey City, New Jersey, US, Ephicacy was founded with the singular objective of being a niche provider of consultancy, functional and capability enhancement services in the area of data management, biostatistics and CDISC conversion, supporting research and clinical trials activities of leaders in the life sciences industry. Ephicacy’s presence in Bangalore, India was established in 2009 as a Center of Excellence (COE), stemming from our conviction of the locally available talent pool. Our investments in hiring and nurturing talent through well established learning and development processes have led to the creation of a competent and committed team. The COE in India is highly delivery driven with well established SOPs. Ephicacy also has an ISO 9001 : 2008 Certified quality systems. Ephicacy extended its consultancy and services operations into the European region during early 2011. Our global delivery organization comprises of a well knit team of experienced data managers, programmers, biostatisticians and domain expert based in the US, India and Europe. The India Centre of Excellence complements the capabilities of our presence in the US and Europe. Ephicacy has stepped in to address the paucity of qualified resources in these functional areas and is able to rapidly fulfill the needs of customers using flexible and bespoke business engagement models. Our highly qualified leadership team handpicks from our pool of qualified professionals to ensure customer projects are well resourced. Today, Ephicacy has proven to be pioneer and continues to be a forerunner in providing ACCURATE, RELIABLE and ON TIME solutions for the life sciences industry.

JPA Health is a comprehensive health communication agency that specializes in public relations, marketing, and advocacy. The company offers a range of services, including earned media, patient advocacy relations, public affairs, and stakeholder engagement. In addition to these core services, JPA Health also provides digital and creative solutions such as design, social media marketing, video production, and animation. By combining strategic insights with creative execution, JPA Health assists clients in developing health campaigns that aim to drive change and achieve measurable outcomes.

Velentium is a designer and manufacturer of therapeutic and diagnostic medical devices, catering to clients of various sizes, from startups to established Fortune 500 companies. The company specializes in cybersecurity, device development, test systems, and medical device manufacturing. Velentium offers expertise in software, usability, cybersecurity, as well as electrical and mechanical development for medical equipment. Through these services, the company helps clients transform their intellectual property into safe and secure products that aim to improve lives. Customer inquiries are addressed through multiple channels, including phone, email, and online applications.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

Bionova Scientific, Inc. was founded by a group of biopharmaceutical specialists and is located in Fremont, CA. This biologics company presents services for cell line development including new biological entity (NBEs) and Biosimilars, cell culture process development, as well as scale- up and tech transfer support in generating biologic medical products.

Axiom provides customer support services for data management, e-clinical management, biostatistics, pharmacovigilance, rescue projects, database migrations, and capabilities for remote and virtual trials. They offer e-clinical technologies like EDC, DM, IWRS, reporting, and data management services to meet the needs of their clients.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

CSM solves complex clinical trial supply problems for biotech and pharmaceutical companies such as limited drug supply, time constraints and mid-study changes. They offer a unique blend of traditional and innovative services that can significantly shorten timelines, reduce costs and improve outcomes for clinical studies.

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with high unmet medical needs. The company is engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia's primary market for its products is the United States, with ongoing efforts to address the needs of targeted patient populations suffering from these conditions.

Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

HRAA interprets data to ensure that healthcare is efficient and effective for everyone by pulling medical data together to create a predictive window to understand cost and revenues looking back and going forward. Founded in 2001 and based out of Plantation, FL, HRAA combines years of industry expertise with best-in-breed technology to create market leading business intelligence products and consulting services to ensure hospitals are reimbursed for every pill they prescribe, every procedure they perform and every test they administer. HRAA both trains and supplies the high tech workforce to hospitals to generate the predictive data used by the whole healthcare system and offers a full suite of solutions needed to keep up with the ever-changing healthcare industry including data analytics software, business intelligence technology, medical coding, auditing, education, revenue cycle consulting, and ICD-10 transition solutions.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

iVantage Health Analytics is a leading advisory and business analytic services company, applying Accelerated Healthcare Transformation and the integrated VantagePoints platform of solutions to drive sustained, evidence based results for healthcare clients. The company's unique combination of technology, content, and expert advisory services accelerates decision making for the new healthcare.

Connecture, Inc. is a web-based platform that specializes in consumer shopping, enrollment, and retention for health insurance distribution in the United States, focusing primarily on the Medicare insurance sector. Founded in 1999 and headquartered in Milwaukee, Wisconsin, the company offers personalized solutions that help users identify suitable health insurance plans based on their individual preferences, health conditions, preferred providers, medications, and anticipated out-of-pocket costs. Connecture serves a diverse clientele, including payers, brokers, government agencies, and online insurance marketplace operators. The company has refined its focus to exclusively cater to the Medicare market, providing tools such as the PlanCompare and DrugCompare product suites through software-as-a-service installations, along with integration, managed hosting, and customer support services. In 2019, Connecture was acquired by Harris Computer Systems, further solidifying its position in the health insurance technology landscape.

Aris Radiology provides a range of professional radiology services to healthcare institutions, including hospitals and surgery centers. The company is Joint Commission certified and collaborates with local medical facilities and radiology groups to deliver a comprehensive hybrid solution. Aris offers high-quality radiologists and ensures 24/7 subspecialty coverage and operational support, which enhances the quality of patient care while maintaining cost-effectiveness. Additionally, the company supports its clients with services such as patient billing, radiologist recruitment, and operational business development. This combination of expertise and service helps improve diagnostic accuracy and patient safety across the healthcare system.

WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.

Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating treatments for diabetes. The company leverages its proprietary VIAdel technology to enhance the formulation of existing drugs, aiming to improve their efficacy and delivery. Biodel's lead product candidate is Linjeta, a rapid-acting mealtime insulin designed for individuals with Type I and Type II diabetes. In addition to Linjeta, the company is exploring earlier-stage candidates that include follow-on and second-generation rapid-acting insulins, a sublingual insulin tablet known as VIAtab, a line of basal insulins, and a glucagon formulation. Through its innovative approach, Biodel aims to address the needs of diabetes patients and improve their treatment options.

American Surgical Professionals is a provider of professional surgical assistant services to hospitals, clinics, surgeons and patients. American Surgical Professionals offers custom tailored solutions to perioperative staffing situations. These include providing surgical specialists on an outsourced, as needed or contract basis.

Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing organization based in Oklahoma City, Oklahoma, specializing in the production of therapeutic proteins and antibodies through mammalian cell culture and microbial fermentation. Founded in 2003, the company offers a range of services including cell line selection, process development, purification, and fill/finish operations, all adhering to current Good Manufacturing Practices (cGMP). Additionally, Cytovance provides analytical development, qualification, and regulatory support, as well as project management and quality assurance services. Its state-of-the-art facilities are FDA inspected, enabling the company to serve biopharmaceutical clients in the United States effectively. As of 2015, Cytovance Biologics operates as a subsidiary of Hepalink USA Inc.

Solta Medical, Inc. is a developer and manufacturer of energy-based medical device systems focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and body contouring, as well as the Fraxel series, which includes systems designed for skin resurfacing, rejuvenation, and treatment of various skin conditions such as acne scars and pigmentation issues. Their systems typically consist of handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical's clientele includes dermatologists, plastic surgeons, and other medical professionals, and its products are marketed through a direct sales force and an international network of distributors. Founded in 1995 and headquartered in Hayward, California, the company previously operated under the name Thermage, Inc. before rebranding in 2009.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

Solta Medical, Inc. is a developer and manufacturer of energy-based medical device systems focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and body contouring, as well as the Fraxel series, which includes systems designed for skin resurfacing, rejuvenation, and treatment of various skin conditions such as acne scars and pigmentation issues. Their systems typically consist of handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical's clientele includes dermatologists, plastic surgeons, and other medical professionals, and its products are marketed through a direct sales force and an international network of distributors. Founded in 1995 and headquartered in Hayward, California, the company previously operated under the name Thermage, Inc. before rebranding in 2009.

Inhibitex specializes in the development of antibody-based products aimed at preventing and treating bacterial and fungal infections. The company emphasizes the creation of small molecule antiviral compounds, with a particular focus on therapies for shingles, also known as herpes zoster, and chronic hepatitis C infections.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Biotronic will continue to lead the intraoperative neural monitoring industry with our breadth of services, patient-centric focus, clinical research & education, geographic concentration and reach, and financial performance. In pursuit of our mission & vision, Biotronic has assembled the clinical expertise and organizational capabilities needed to provide excellence in care and prompt, reliable service with managed cost efficiency. As experts in this specialty, we take pride in partnering with hospitals and surgeons to obtain and analyze critical information during selective surgeries which place neural structures at risk. The information we provide allows surgeons to intervene immediately to mitigate problems that may otherwise go undetected until after completion of the surgery. We help you improve your quality and do so within a cost-effective partnership.

As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

CellCarta's Mission is centered on collaborating and partnering with pharmaceutical and biotech companies through proteomics and immune monitoring enabling the acceleration of precision medicine in drug development. With a vision and deep understanding of the needs for complex immune monitoring in novel drug development, Caprion integrated ImmuneCarta (formerly known as National Immune Monitoring), with its established and proven proteomics service, ProteoCarta. Together, Caprion now offers a fully integrated and unique service offering to its partners.

Panacos Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of small-molecule oral drugs targeting human immunodeficiency virus (HIV) and other viral diseases. Founded in 1999 and based in Watertown, Massachusetts, the company employs innovative technologies to identify novel targets in the viral life cycle, particularly in areas such as virus maturation and fusion. Its product pipeline includes advanced programs aimed at inhibiting HIV maturation, representing second- and third-generation therapeutic options.

Forbes Medi-Tech Inc. is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products.